| Identification | Back Directory | [Name]
Carbamic acid, N-[(3R,7S)-7-[4-(3-chloro-2,6-difluorophenyl)-5,6-dihydro-2-oxo-1(2H)-pyridinyl]-2,3,4,5,6,7-hexahydro-3-methyl-2-oxo-1H-8,12-metheno-1,9-benzodiazacyclotetradecin-15-yl]-, methyl ester | [CAS]
1551459-37-0 | [Synonyms]
Carbamic acid, N-[(3R,7S)-7-[4-(3-chloro-2,6-difluorophenyl)-5,6-dihydro-2-oxo-1(2H)-pyridinyl]-2,3,4,5,6,7-hexahydro-3-methyl-2-oxo-1H-8,12-metheno-1,9-benzodiazacyclotetradecin-15-yl]-, methyl ester | [Molecular Formula]
C31H29ClF2N4O4 | [MOL File]
1551459-37-0.mol | [Molecular Weight]
595.04 |
| Hazard Information | Back Directory | [Description]
FXIa-6f is a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species | [Uses]
FXIa-IN-6 is a potent FXIa inhibitor with selectivity against most of the relevant serine proteases (Ki = 0.3 nM). | [References]
[1] Yang W, et al. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species. J Med Chem. 2020 Jul 9;63(13):7226-7242. DOI:10.1021/acs.jmedchem.0c00464 |
|
|